Investigating the motivations and barriers of people's participation in the vaccination program against covid19 disease in Semnan city in 1400- a qualitative study

authors:

avatar Hemmati Hemmati , avatar Majid Mirmohammadkhani ORCID , avatar saharnaz nedjat ORCID , avatar Ehsan Mostafavi , avatar Alireza Biglari , avatar Mohsen Asadi-Lari , *

Koomesh: Vol.25, issue 3; 363-377
published online: September 07, 2023
article type: Research Article
received: January 01, 2023
accepted: June 07, 2023

how to cite: Hemmati H, Mirmohammadkhani M, nedjat S, Mostafavi E, Biglari A, et al. Investigating the motivations and barriers of people's participation in the vaccination program against covid19 disease in Semnan city in 1400- a qualitative study. koomesh. 2023;25(3):e152835. 

Abstract

Introduction: Vaccines are the most successful and cost-effective public health tools that have helped control, eliminate, or eradicate many infectious diseases, and are the key intervention to end the COVID-19 pandemic. Therefore, the World Health Organization recommends that to increase the acceptance of vaccination, each country should identify and provide appropriate strategies to increase the motivation and desire of people and also to solve the challenges created to receive the vaccine. The purpose of this qualitative study was to identify the motivations and challenges of the participants in the COVID-19 vaccination program, particularly with PastoCovac which was jointly developed by the Finlay Institute of Vaccines in Cuba (IFV) and Pasteur Institute of Iran (PII), and to achieve a better understanding of the challenges of vaccination in the Iranian society, and to find ways to increase and strengthen the motivations. Materials and Methods: A purposeful sample of people who visited a major urban health center in Semnan were approached for this qualitative study to reach data saturation (30 people) with open questions in a 30-minute interview. Relatively, after conducting the interview, the audio file was listened to carefully and if necessary intermittently by the interviewer and transcribed. The overt and hidden content of data obtained from the statements were checked and then the traditional content analysis was used to develop meaningful clusters of themes. Results: The main themes of people's motivations identified in the current research include controlling disease and reducing mortality, protecting health and establishing collective safety, improving social and economic conditions, advancing medical knowledge, trust and credibility of the Pasteur Institute of Iran (PII), acceptable possible side effects and The high effectiveness, local production of the vaccine are the unique characteristics of the vaccine, while the obstacles identified are: false and ignorant beliefs, lack of trust in the vaccine, people's fear and worry of side effects, the unique characteristics of the vaccine, lack of universal acceptability, insufficient recognition of vaccine characteristics. Conclusion: PastoCovac as one of the major vaccines against COVID-19 developed jointly by PII and IFV, was acceptable to the Iranian population in every aspect. PastoCovac, therefore, played an important role in achieving e acceptable levels of safety in the country during the pandemic.

References

  • 1.

    Christie A, Brooks JT, Hicks LA, Sauber-Schatz EK, Yoder JS, Honein MA. Morbidity and mortality weekly report guidance for implementing COVID-19 prevention strategies in the context of varying community transmission levels and vaccination coverage. Morbid Mortal Weekly Rep 2021; 70: 1044.

  • 2.

    Bono SA, Villela EF de M, Siau CS, Chen WS, Pengpid S, Hasan MT, et al. Factors affecting COVID-19 vaccine acceptance: an international survey among low-and middle-income countries. Vaccines 2021; 9.

  • 3.

    Andre FE. Policy and practice Vaccination and reduction of disease and inequity. Bull World Health Organ 2008; 86.

  • 4.

    Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA 2020; 323: 1406-1407.

  • 5.

    Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et al. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N Engl J Med 2020; 382: 2081-2090.

  • 6.

    WHO. Contact tracing and quarantine in the context of the Omicron SARS-CoV-2 variant. 2022; 1-18. Available from: https://apps.who.int/iris/rest/bitstreams/1411031/retrieve.

  • 7.

    ten threats to global health in 2019. https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019. Accessed 2020.

  • 8.

    Royal Society T. COVID-19 vaccine deployment: behaviour, ethics, misinformation and policy strategies. 2020. https://royalsociety.org/-/media/policy/projects/set-c/set-c-vaccine-deployment.pdf.

  • 9.

    Report of the sage working group on vaccine hesitancy 12 November 2014. Hesitancy https://www.who.int/immunization/sage/meetings/2014/ctober/SAGE_working_group_revised_report_vaccine_hesitancy.pdf. Accessed 2020.

  • 10.

    Shatizadeh Malekshahi S, Tahamtan A, Salimi V. Whole-inactivated SARS-CoV-2 vaccines: from fear to hope. Koomesh 2022; 24: 567-569. (Persian).

  • 11.

    Wang Z, Fang Y, Yu F, Chan PS, Chen S. Facilitators and barriers to Take up a COVID-19 Vaccine booster dose among community-dwelling older adults in Hong Kong: A Population-Based Random Telephone Survey. Vaccines 2022; 10: 1-16.

  • 12.

    French J, Deshpande S, Evans W, Obregon R. Key guidelines in developing a pre-emptive COVID-19 vaccination uptake promotion strategy. Int J Environ Res Public Health 2020; 17: 1-14.

  • 13.

    https://en.pasteur.ac.ir/News-&-Events/Efficacy-and-Safety-of-Soberana/PastoCovac-vaccine;-A-Randomized-Clinical-Trial-in-Pasteur-Institute-of-Iran.

  • 14.

    https://behdasht.gov.ir/%D8%A7%D8%AE%D8%A8%D8%A7%D8%B1/%D8%B5%D9%81%D8%AD%D9%87:680.

  • 15.

    https://behdasht.gov.ir/%D8%A7%D8%AE%D8%A8%D8%A7%D8%B1/%D8%B5%D9%81%D8%AD%D9%87:680.

  • 16.

    Allahverdi N, Parizad N, Shahbaz A. Nursing research in Iran and the world from the perspective of nursing professors: A qualitative study.##.

  • 17.

    https://www.ecdc.europa.eu/en/seasonal-influenza/facts/factsheet.

  • 18.

    https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-vaccines.

  • 19.

    https://www.who.int/philippines/news/detail/11-03-2022-opinion-is-the-pandemic-ending-soon.

  • 20.

    https://sgp.fas.org/crs/row/R46270.pdf.

  • 21.

    https://www.health.gov.au/topics/aged-care/managing-covid-19/for-older-people-and-carers.

  • 22.

    https://publichealth.wustl.edu/why-older-people-are-among-the-first-to-get-the-vaccine/##.

  • 23.

    MacDonald NE, Eskola J, Liang X, Chaudhuri M, Dube E, Gellin B, et al. Vaccine hesitancy: Definition, scope and determinants. Vaccine 2015; 33: 4161-4164.

  • 24.

    Larson HJ, Jarrett C, Eckersberger E, Smith DM, Paterson P. Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: A systematic review of published literature, 2007-2012. Vaccine 2014; 32: 2150-2159.

  • 25.

    Duffy B. Coronavirus: vaccine misinformation and the role of social media. https://www.kcl.ac.uk/policy-institute/assets/coronavirusvaccine- misinformation. pd.

  • 26.

    https://www.who.int/docs/default-source/covid-19-vaccines-safety-surveillance-manual/covid19vaccines_manual_aefi_20210104.pdf.

  • 27.

    https://www.who.int/news-room/feature-stories/detail/side-effects-of-covid-19-vaccines##.

  • 28.

    Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 2020; 586: 589-593.

  • 29.

    Walsh EE, Frenck RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med 2020; 383: 2439-2450.

  • 30.

    https://www.who.int/initiatives/act-accelerator/covax.

  • 31.

    https://www.researchgate.net/publication/323474448_Pasteur_Institute_of_Iran_History_and_Services.